Activation of Ventral Tegmental Area 5-HT2C Receptors Reduces Incentive Motivation

Neuropsychopharmacology

Volumn 42, Issue 7, 2017, Pages 1511-1521

  Valencia Torres, Lourdes ^a   Olarte Sánchez, Cristian M ^a   Lyons, David J ^a   Georgescu, Teodora ^a   Greenwald Yarnell, Megan ^b   Myers, Martin G ^b   Bradshaw, Christopher M ^c   Heisler, Lora K ^a  

^a ROWETT RESEARCH INSTITUTE   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; CLOZAPINE N OXIDE; LORCASERIN; PROTEIN C FOS; SEROTONIN 2C RECEPTOR; BENZAZEPINE DERIVATIVE; SEROTONIN 2 AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE; ARTICLE; CHOCOLATE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; GABAERGIC SYSTEM; HUNGER; IMMUNOHISTOCHEMISTRY; INSTRUMENTAL CONDITIONING; MALE; MATHEMATICAL MODEL; MOTIVATION; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REWARD; VENTRAL TEGMENTUM; ANIMAL; DRUG EFFECTS; EATING; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; TRANSGENIC MOUSE;

ANIMALS; BENZAZEPINES; CONDITIONING, OPERANT; EATING; FEMALE; MALE; MICE; MICE, TRANSGENIC; MOTIVATION; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; VENTRAL TEGMENTAL AREA;

EID: 85008259936     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.264     Document Type: Article

References (49)

1. Aberman JE, Ward SJ, Salamone JD (1998). Effects of dopamine antagonists and accumbens dopamine depletions on time-constrained progressive-ratio performance. Pharmacol Biochem Behav 61: 341-348.
2. Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA et al (2009). Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron 63: 27-39.
3. Bezzina G, Body S, Cheung TH, Hampson CL, Bradshaw CM, Glennon JC et al (2015). Evidence for a role of 5-HT2C receptors in the motor aspects of performance, but not the efficacy of food reinforcers, in a progressive ratio schedule. Psychopharmacology 232: 699-711.
4. Blundell JE (1986). Serotonin manipulations and the structure of feeding behaviour. Appetite 7 Suppl: 39-56.
5. Bradshaw CM, Killeen PR (2012). A theory of behaviour on progressive ratio schedules, with applications in behavioural pharmacology. Psychopharmacology 222: 549-564.
6. Bubar MJ, Cunningham KA (2007). Distribution of serotonin 5-HT2C receptors in the ventral tegmental area. Neuroscience 146: 286-297.
7. Bubar MJ, Stutz SJ, Cunningham KA (2011). 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccum-bens pathway. PLoS One 6: e20508.
8. Burbassi S, Cervo L (2008). Stimulation of serotonin2C receptors influences cocaine-seeking behavior in response to drug-associated stimuli in rats. Psychopharmacology 196: 15-27.
9. Burke LK, Doslikova B, D'Agostino G, Greenwald-Yarnell M, Georgescu T, Chianese R et al (2016). Sex difference in physical activity, energy expenditure and obesity driven by a subpopulation of hypothalamic POMC neurons. Mol Metab 5: 245-252.
10. Burke LK, Heisler LK (2015). 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol 27: 389-398.
11. Burke LK, Doslikova B, D'Agostino G, Garfield AS, Farooq G, Burdakov D et al (2014). 5-HT obesity medication efficacy via POMC activation is maintained during aging. Endocrinology 155: 3732-3738.
12. DiLeone RJ, Taylor JR, Picciotto MR (2012). The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction. Nat Neurosci 15: 1330-1335.
13. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (2000). Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin (2C) receptors. Brain Res 865: 85-90.
14. Doslikova B, Garfield AS, Shaw J, Evans ML, Burdakov D, Billups B et al (2013). 5-HT2C receptor agonist anorectic efficacy potentiated by 5-HT1B receptor agonist coapplication: an effect mediated via increased proportion of pro-opiomelanocortin neurons activated. J Neurosci 33: 9800-9804.
15. Filip M, Spampinato U, McCreary AC, Przegalinski E (2012). Pharmacological and genetic interventions in serotonin (5-HT) (2C) receptors to alter drug abuse and dependence processes. Brain Res 1476: 132-153.
16. Fletcher PJ, Rizos Z, Noble K, Soko AD, Silenieks LB, Le AD et al (2012). Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement. Neuropharmacology 62: 2288-2298.
17. Fletcher PJ, Tampakeras M, Sinyard J, Slassi A, Isaac M, Higgins GA (2009). Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice. Neuropharmacology 57: 259-267.
18. Graves SM, Viskniskki AA, Cunningham KA, Napier TC (2013). Serotonin(2C) receptors in the ventral pallidum regulate motor function in rats. Neuroreport 24: 605-608.
19. Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA (2011). Serotonergic anti-obesity agents: past experience and future prospects. Drugs 71: 2247-2255.
20. Harvey-Lewis C, Li Z, Higgins GA, Fletcher PJ (2015). The 5-HT receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. Neuropharmacology 101: 237-245.
21. Hayes DJ, Mosher TM, Greenshaw AJ (2009). Differential effects of 5-HT2C receptor activation by WAY 161503 on nicotine-induced place conditioning and locomotor activity in rats. Behav Brain Res 197: 323-330.
22. Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL et al (2002). Activation of central melanocortin pathways by fenflur-amine. Science 297: 609-661.
23. Higgins GA, Silenieks LB, Rossmann A, Rizos Z, Noble K, Soko AD et al (2012). The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. Neuropsy-chopharmacology 37: 1177-1191.
24. Higgs S, Cooper AJ, Barnes NM (2016). The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour. Psychopharmacology 233: 417-424.
25. Hill AJ, Blundell JE (1990). Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges. Int J Obes 14: 219-233.
26. Hodos W (1961). Progressive ratio as a measure of reward strength. Science 134: 943-944.
27. Killeen PR (1994). Mathematical principles of reinforcement. Behav Brain Sci 17: 105-172.
28. Killeen PR, Posadas-Sanchez D, Johansen EB, Thrailkill EA (2009). Progressive ratio schedules of reinforcement. J Exp Psychol Anim B 35: 35-50.
29. Kranz GS, Kasper S, Lanzenberger R (2010). Reward and the serotonergic system. Neuroscience 166: 1023-1035.
30. Lam DD, Przydzial MJ, Ridley SH, Yeo GSH, Rochford JJ, O'Rahilly S et al (2008). Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology 149: 1323-1328.
31. Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A et al (2011). Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther 338: 890-896.
32. Martin CK, Redman LM, Zhang J, Sanchez M, Anderson CM, Smith SR et al (2011). Lorcaserin, A 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocr Metab 96: 837-845.
33. Meltzer HY, Roth BL (2013). Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs. J Clin Invest 123: 4986-4991.
34. Miguelez C, Morera-Herreras T, Torrecilla M, Ruiz-Ortega JA, Ugedo L (2014). Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front Neural Circuits 8: 21.
35. Navailles S, Moison D, Cunningham KA, Spampinato U (2008). Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. Neuropsychopharmacology 33: 237-246.
36. Olarte-Sanchez CM, Valencia-Torres L, Cassaday HJ, Bradshaw CM, Szabadi E (2013). Effects of SKF-83566 and haloperidol on performance on progressive ratio schedules maintained by sucrose and corn oil reinforcement: quantitative analysis using a new model derived from the Mathematical Principles of Reinforcement (MPR). Psychopharmacology 230: 617-630.
37. Olarte-Sanchez CM, Valencia-Torres L, Cassaday HJ, Bradshaw CM, Szabadi E (2015). Quantitative analysis of performance on a progressive-ratio schedule: effects of reinforcer type, food deprivation and acute treatment with Delta(9)-tetrahydrocanna-binol (THC). Behav Process 113: 122-131.
38. Olarte-Sanchez CM, Valencia Torres L, Body S, Cassaday HJ, Bradshaw CM, Szabadi E et al (2012). A clozapine-like effect of cyproheptadine on progressive ratio schedule performance. J Psychopharmacol 26: 857-870.
39. Paxinos G, Franklin K (2001). The Mouse Brain in Stereotaxic Coordinates, 2nd edn. Academic Press: San Diego.
40. Rezvani AH, Cauley MC, Levin ED (2014). Lorcaserin, a selective 5-HT(2C) receptor agonist, decreases alcohol intake in female alcohol preferring rats. Pharmacol Biochem Behav 125: 8-14.
41. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
42. Salamone JD, Correa M (2013). Dopamine and food addiction: lexicon badly needed. Biol Psychiatry 73: e15-e24.
43. Skjoldager P, Winger G, Woods JH (1993). Effects of GBR 12909 and cocaine on cocaine-maintained behavior in rhesus monkeys. Drug Alcohol Depend 33: 31-39.
44. Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D et al (2008). Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther 325: 577-587.
45. Urban DJ, Roth BL (2015). DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu Rev Pharmacol 55: 399-417.
46. Valencia-Torres L, Bradshaw CM, Bouzas A, Hong E, Orduña V (2014). Effect of streptozotocin-induced diabetes on performance on a progressive ratio schedule. Psychopharmacology 231: 2375-2384.
47. Vickers SP, Clifton PG (2012). Animal models to explore the effects of CNS drugs on food intake and energy expenditure Neuro-pharmacology 63: 124-131.
48. Wynne CD, Staddon JE, Delius JD (1996). Dynamics of waiting in pigeons. J Exp Anal Behav 65: 603-618.
49. Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, Choi MJ et al (2008). 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron 60: 582-589.